A seven-year-old research project inside a French medical AI company has broken off to pursue its own fortune in precision oncology.
Waiv, the newly independent diagnostics arm of Paris-based Owkin, emerged from stealth on March 12, 2026, with $33 million in fresh capital and a portfolio of cancer-detection tools that have been quietly validated in clinical settings for years. The announcement marks the formal separation of what was once Owkin Dx—a diagnostic division that some industry observers had long speculated might eventually stand alone.
The financing was co-led by OTB Ventures, a European deep-tech investor managing roughly €350 million, and Alpha Intelligence Capital, which oversees more than $450 million dedicated to AI-focused companies. Serena Data Ventures, Karista, and SistaFund joined the round as well.
What the company didn't say: whether this counts as a seed or Series A. Waiv labeled it simply a "financing round" in its press materials, leaving the staging question unanswered. That ambiguity isn't unusual for spin-outs, which often carry both developmental momentum and commercial traction into their first external raise, complicating traditional venture nomenclature.
The Mechanics of a Spin-Out
Corporate separations rarely happen overnight, and Waiv's path to independence has been methodical—perhaps more so than most. French registry filings trace the process back over a year. Owkin DX SAS was incorporated on December 18, 2024, as a wholly owned subsidiary of Owkin France. On July 23, 2025, Owkin transferred its entire diagnostics operation to the new entity under French partial asset contribution rules. By October, the subsidiary's share capital had grown to just over €800,000, reflecting both the diagnostics business and additional injections of capital.
A month later came the trademark filing. The name "WAIV" was filed with the European Union Intellectual Property Office on November 3, 2025, covering AI-driven diagnostics, clinical trial design, and medical imaging analysis. The trademark was published on November 28, 2025.
Owkin itself has signaled the shift publicly. Its website now lists Waiv among its "organisation" alongside Bioptimus, a computational biology spinoff that raised $35 million two years ago, and Epkin, another affiliated entity. The parent company appears to be cultivating a portfolio approach: incubate advanced research inside, then spin promising projects into focused commercial vehicles.
What Waiv Actually Does
The core technology is multimodal AI applied to digital pathology—essentially, teaching algorithms to read tissue samples the way a pathologist might, but with the ability to integrate genomic, clinical, and imaging data simultaneously. Waiv's platform, called Destra, combines proprietary foundational models with what the company describes as a clinical validation framework.
The inherited product lineup includes RlapsRisk BC, a breast cancer relapse prediction tool that has secured CE-IVD certification in Europe. There's MSIntuit Suite, designed to pre-screen colorectal tumors for microsatellite instability. And then there's BRCAura, a germline mutation pre-screener developed through a partnership with AstraZeneca that was announced on October 2, 2024.
A separate collaboration with MSD, dating to December 2023, focuses on MSI-H diagnostics across multiple tumor types. These aren't purely academic exercises—Waiv positions the tools as commercially deployable products, not just research prototypes.
The company also taps into the PortrAIt consortium, a data network that supports biomarker discovery. Access to large, diverse datasets remains a competitive advantage in medical AI, where model performance hinges on training breadth.
Timing and Context
Digital pathology has reached an inflection point of sorts. PathAI, one of the better-funded U.S. players in the space, announced a multi-year deal with Northwestern Medicine last June to deploy its AISight platform across the health system's pathology labs. Similar partnerships have cropped up elsewhere, suggesting that hospital administrators and laboratory directors are increasingly willing to integrate AI into diagnostic workflows.
For Waiv, the $33 million provides enough runway to expand beyond Europe and pursue regulatory clearances in additional markets. CEO and co-founder Meriem Sefta will oversee that effort, though the company has remained tight-lipped about ownership stakes and valuation.
The broader question is whether precision diagnostics can scale as a standalone business—or whether these tools ultimately get absorbed back into pharma companies and health systems as enabling technologies. Waiv is betting on the former. The spin-out structure suggests confidence that diagnostics justify a dedicated entity, separate from Owkin's drug discovery ambitions.
Whether that confidence translates into a durable independent company or an attractive acquisition target down the line remains to be seen. For now, Waiv has capital, clinical validation, and a name that breaks cleanly from its corporate parent. That's more than most spin-outs start with.
